CERE - Cerevel more than doubles on early-stage results of schizophrenia candidate

babyrhino/iStock via Getty Images Shares of Cerevel Therapeutics ([[CERE]] +128.8%) have more than doubled today after the company this morning positive positive results on its novel phase 1b candidate for schizophrenia, CVL-231. The company plans to advance the candidate into phase 2 as well as explore the drug in other indications, such as dementia-related psychosis. Earlier this month, the company received Fast Track designation from the FDA for another candidate, CVL-871, for dementia-related apathy. Cerevel's most advanced asset is tavadapon for early- and late-stage Parkinson's disease. Also in the pipeline is darigabat for epilepsy and anxiety, and CVL-936 for substance use disorder. Cerevel was founded in 2018 by Pfizer and Bain Capital with the drugmaker spinning off some of its neurology candidates into the new company.

For further details see:

Cerevel more than doubles on early-stage results of schizophrenia candidate